All In Biotech

Drug Trial Radar · NCT05382559

A Study of ASP3082 in Adults With Advanced Solid Tumors

A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

681

Planned (sponsor's estimate)

Start

Jun 8, 2022

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
May 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2 parts. In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab, to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP3082. The panel will do this for each group until all groups have received ASP3082 (by itself or together with cetuximab) or until suitable doses have been selected for Part 2. In Part 2, ASP3082 will be given in by itself, or in combination with the other study treatments. Study treatments will be given through a vein. This is called an infusion. Each treatment cycle is 21 or 28 days long. They will continue treatment until: they have medical problems from the treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop treatment.

Conditions

  • Solid Tumor

Interventions

  • SetidegrasibDrug

    Intravenous Infusion

  • CetuximabDrug

    Intravenous Infusion

  • LeucovorinDrug

    Intravenous Infusion

  • OxaliplatinDrug

    Intravenous Infusion

  • FluorouracilDrug

    Intravenous Infusion

  • IrinotecanDrug

    Intravenous Infusion

  • Nanoparticle albumin-bound-paclitaxelDrug

    Intravenous Infusion

  • GemcitabineDrug

    Intravenous Infusion

  • DocetaxelDrug

    Intravenous Infusion

  • PembrolizumabDrug

    Intravenous Infusion

  • CisplatinDrug

    Intravenous Infusion

  • CarboplatinDrug

    Intravenous Infusion

  • PemetrexedDrug

    Intravenous Infusion

  • Liposomal IrinotecanDrug

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs)Time frame: Up to 28 Days
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to 48 months
  3. Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to 48 months
  4. Number of Participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to 48 months
  5. Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)Time frame: Up to 48 months
  6. Number of Participants with vital sign abnormalities and/or adverse events (AEs)Time frame: Up to 48 months
  7. Number of Participants with physical exam abnormalities and/or adverse eventsTime frame: Up to 48 months
  8. Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Up to 48 months

Locations

68 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • UCLA Santa Monica Hematology Oncology

    Santa Monica, California · Recruiting

  • Denver HealthONE Drug Development Unit

    Denver, Colorado · Recruiting

  • Smilow Cancer Center at Yale New Haven Hospital

    New Haven, Connecticut · Recruiting

  • Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • University of Florida, Davis Cancer Center

    Gainesville, Florida · Recruiting

  • Florida Cancer Specialist

    Lake Mary, Florida · Terminated

  • Florida Cancer Specialists & Research Institute Sarasota

    Sarasota, Florida · Recruiting

  • University of Kansas Medical Center

    Westwood, Kansas · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Trinity Health Ann Arbor Hospital

    Ypsilanti, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • Columbia University - Herbert Irving Comprehensive Cancer Center

    New York, New York · Terminated

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Rochester Medical Center James P. Wilmot Cancer Center

    Rochester, New York · Recruiting

  • Case Western

    Cleveland, Ohio · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Terminated

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Oncology - Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • University of Wisconsin Hospital

    Madison, Wisconsin · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Xuhui District, Shanghai Municipality, China · Recruiting

  • Site FR33002

    Bordeaux, France · Recruiting

  • Site FR33001

    Lyon, France · Recruiting

  • Site FR33005

    Lyon, France · Recruiting

  • Site FR33003

    La Tronche, Grenobele, France · Recruiting

  • Site FR33004

    Villejuif, Île-de-France Region, France · Recruiting

  • Osaka International Cancer Institute

    Osaka, Japan · Recruiting

  • Aichi Cancer Center

    Nagoya, Aichi-ken, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Recruiting

  • Shikoku Cancer Center

    Matsuyama, Ehime, Japan · Recruiting

  • Kurume University Hospital

    Kurume, Fukuoka, Japan · Recruiting

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.